CELG News and Press, Celgene Corporation From 08/27/19

Merger activity remained unchanged last week with four new deals announced and one deal closing. Deal Statistics: New Deals: The acquisition of DryShips ( DRYS ) in a going private transaction for $915.73 million or $5.25 per share in cash. We added DRYS as a potential deal to t...

Investors trying to divine the state of the trade war with China were heartened by optimistic comments from President Trump on Monday, sending major benchmarks higher. The  Dow Jones Industrial Average (DJINDICES: ^DJI)  and the  S&P 500 (SNPINDEX: ^GSPC) both gained abou...

Amgen (NASDAQ: AMGN) CEO Bob Bradway said in the big biotech's second-quarter conference call last month that Amgen was "looking at ways to grow through business development." We now know one of those ways. On Monday morning, Amgen announced that it was buying psoriasis and psoriatic arth...

Stop! My original title for this morning's piece was Stop Selling! That's because the futures were down very hard last night. If you are in the habit of selling on political news over this president's tweets, you have lost money. If you sold Friday and want to buy this morning because the ...

Amgen (NASDAQ: AMGN ) has agreed to acquire global rights to Celgene's (NASDAQ: CELG ) psoriasis med Otezla (apremilast) for $13.4B in cash. Bristol-Myers Squibb (NYSE: BMY ) is divesting the PDE4 inhibitor in order to receive regulatory sign-off on its merger with Celgene. The transaction...

THOUSAND OAKS, Calif. , Aug. 26, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today that it has entered into an agreement with Celgene Corporation (NASDAQ: CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (NYSE: BMY) to acquire worl...

Cancer treatment is one of the hottest areas of healthcare investing these days, with personalized medicine like genetic therapies providing new promises of treatment and potential cures. Still, despite the progress that researchers have made, there are still plenty of false starts and treatme...

Biogen (NASDAQ: BIIB) and Celgene (NASDAQ: CELG) claimed similar market caps earlier this year. That's not the case now, though. In March, Biogen announced that it was halting late-stage clinical studies for its once-promising Alzheimer's disease drug, aducanumab . The biotech's sh...

NetworkNewsWire Editorial Coverage : Biotech and biopharma industry leaders are posting record financials and hitting milestone markers in their research and growth, good indicators of a strong market with potential for robust returns on investment. Genprex Inc. (NASDAQ: GNPX) ( GNPX Profi...

CELG stock is currently on a good run of good news in 2019 after a few years of bad news from Celgene Corporation (NASDAQ:CELG). In May, the company secured US Food and Drug Administration approval for a combination of Rituxan and Revlimid, which is a second-line follicular lymphoma and...